DelveInsight has launched a new report on “Dravet Syndrome Market”
Dravet syndrome (DS) is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. It has been defined as a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.
Request for free sample copy- https://www.delveinsight.com/sample-request/dravet-syndrome-market
The Dravet Syndrome market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dravet Syndrome market
Dravet Syndrome Treatment
Current treatment options are limited, and the constant care required for someone suffering from Dravet syndrome can severely impact the patient’s and the family’s quality of life. Patients with Dravet syndrome face a 15-20% mortality rate due to SUDEP (Sudden Unexpected Death in Epilepsy), prolonged seizures, seizure-related accidents such as drowning, and infections.
Dravet Syndrome Market Disease
Three stages are usually identified in association with DS with “Febrile stage” being the first among them, Worsening stage” follows between 1 and 5 years of age and “Stabilization stage” begins by the end of the first decade in which seizures are less frequent
The Signs and Symptoms of the disease involve seizures, ataxia (balance problems), motor impairment, cognitive impairment, behavioral problems, infections, bone problems, and heart rhythm irregularities.
Dravet Syndrome Companies
Dravet Syndrome Drugs
Despite these shortcomings, in recent years Dravet syndrome has received significant attention from the pharmaceutical industry, and the pipeline has matured to include not only symptomatic but also disease-modifying treatment. At present, Pharmacological management of Dravet syndrome focuses largely on the use antiepileptic drugs such as Valproic Acid, Clobazam, Topiramate, Levetiracetam, Zonisamide and Stiripentol.
Dravet Syndrome Report Highlights
Table of content
1 Key Insights
2 Executive Summary of Dravet Syndrome
3 SWOT Analysis for Dravet Syndrome
4 Dravet Syndrome Market Overview at a Glance
5 Dravet Syndrome: Disease Background and Overview
6 Epidemiology and Patient Population
7 Country Wise-Epidemiology of Dravet Syndrome
8 United States
9 EU-5
10 Germany
11 France
12 Italy
13 Spain
14 United Kingdom
15 Japan
16 Treatment of Dravet Syndrome
17 Unmet Needs
18 Organizations contributing toward Dravet Syndrome
19 KOL’s Views: Dravet Syndrome
20 Case Studies
21 Marketed Drugs
22 Emerging Therapies
23 Dravet Syndrome: Seven Major Market Analysis
24 Market Outlook by Country
25 Market Drivers
26 Market Barriers
27 Appendix
28 Report Methodology
29 DelveInsight Capabilities
30 Disclaimer
31 About DelveInsight
Reasons to buy
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/